No association between body mass index and immunotoxicity or clinical outcomes for immune checkpoint inhibitors. Supplementary Table
Supplementary Table 1. Development of immune-related adverse events (irAEs) and treatment response in patients with melanoma treated with immune checkpoint inhibitors at a single center, categorized by body mass index. Values are expressed as n (%), unless otherwise specified.